Menu Back to DIA-North-Africa-Regulatory-Conference

Overview

The aim of the North Africa Regulatory Conference is to bring together key stakeholders and to discuss ways of improving access to medicines and therapies for the citizens and patients in the Region.

The Region is moving ahead rapidly in playing a major role in innovation and development of new medicines. A local as well as global perspective will support all key stakeholders in exchanging the current state of the art, best practices and future requirements as well as focus on getting guidelines into practice and practice into guidelines.

This regulatory conference will serve as an international and neutral forum for attendees to discuss how the different countries can play a leadership role in drug development. Speakers from local and international regulatory agencies, industry, and academia will present and will lead the panels and sessions.

The conference offers the opportunity for key stakeholders, including representatives from health authorities, local and multinational pharmaceutical companies, academia, and international governmental and non- governmental organisations to exchange progressive views on key topics of interest and identify focus areas for ongoing efforts aimed to increase patient access to new and improved medicines.

Download Programme

Featured topics

  • Regulatory System Strengthening
  • Good Regulatory Practices in the North Africa Region and Beyond
  • Biotherapeutic Products and Biosimilars
  • Medical Devices and in-vitro diagnostics
  • OTCs Status
  • Safety and Pharmacovigilance
  • Sub-standards and Falsified Medicines
  • Innovative Approaches in Medicine Developments

Who should attend?

The conference is directed at key stakeholders that are active or interested in this diverse and changing region, including representatives from regulatory agencies, ministries of health, local and multi-national pharmaceutical companies. You will have the opportunity to meet and exchange views, discuss topics of interest and identify actions to increase patient access to new and improved medicines and therapies:

  • Representatives from health authorities
  • Professionals in:
    • Regulatory affairs
    • Quality assurance
    • Clinical
    • Safety
    • Research & Development
  • Other professionals involved in or interested in the aspects surrounding:
    • Registration and life cycle management of medicinal products
    • Regulatory convergence

Program Committee

  • Hala Kanaan Abu-Ghazalah
    Hala Kanaan Abu-Ghazalah Regulatory Affairs Director
    Pfizer Nutrition FZ LLC, United Arab Emirates
  • Sarah  Adam
    Sarah Adam Head of Regulatory Science Policy – Africa
    IFPMA, Switzerland
  • Samvel  Azatyan, MD, PhD
    Samvel Azatyan, MD, PhD Group Lead, Regulatory Networks and Harmonization (RNH/RSS)
    World Health Organization (WHO), Switzerland
  • Samia  Beddek
    Samia Beddek Head of Regulatory Affairs/ Qualified Person
    Sanofi, Algeria
  • Sanaa  Cherradi
    Sanaa Cherradi Regulatory Affairs Head MTL
    Novartis Pharma Maroc, Morocco
  • Nevena  Miletic
    Nevena Miletic Regulatory Policy Lead – EEMEA & Chair of IFPMA CPP Network
    F.Hoffmann-La Roche ltd, Switzerland
  • Smail  Nahmed
    Smail Nahmed Regulatory Affairs Manager North and West Africa
    Merck, Morocco
  • Jasmin  Badcock
    Jasmin Badcock Associate Director, EMEA Emerging Markets Regulatory Liaison
    Johnson & Johnson, United Kingdom
  • Kawaldip  Sehmi
    Kawaldip Sehmi CEO
    International Alliance Of Patients' Organizations (IAPO), United Kingdom
  • Myriam  Sedrati
    Myriam Sedrati Regulatory Affairs Director North and West Africa
    Merck Sharp & Dohme, Morocco
  • Yacine  Sellam, PharmD, PhD
    Yacine Sellam, PharmD, PhD President
    Algerian Society for Regulatory Affairs & Pharmacoeconomics (SAARPE), Algeria
Load More

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download